Acro Biomedical Co., Ltd.
ACBM
$0.0007
-$0.1043-99.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.45% | -13.59% | -45.40% | -99.23% | -99.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.45% | -13.59% | -45.40% | -99.42% | -99.72% |
| Operating Income | -49.45% | 13.59% | 45.40% | 99.42% | 99.72% |
| Income Before Tax | -54.46% | 8.85% | 41.21% | 99.36% | 99.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.46% | 8.85% | 41.21% | 99.36% | 99.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.46% | 8.85% | 41.21% | 99.36% | 99.68% |
| EBIT | -49.45% | 13.59% | 45.40% | 99.42% | 99.72% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -50.00% | 0.00% | 33.33% | 99.25% | 99.62% |
| Normalized Basic EPS | -100.00% | 0.00% | 50.00% | 99.39% | 99.70% |
| EPS Diluted | -50.00% | 0.00% | 33.33% | 99.25% | 99.62% |
| Normalized Diluted EPS | -100.00% | 0.00% | 50.00% | 99.39% | 99.70% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |